The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.
Robert Fox, MD, FAAN
Advertisement
Articles by Robert Fox, MD, FAAN
Advertisement
Latest Updated Articles
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential BiomarkersPublished: June 12th 2025 | Updated: June 16th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting MembersPublished: June 10th 2025 | Updated: June 12th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular CarePublished: June 2nd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment LandscapePublished: June 3rd 2025 | Updated: June 11th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201Published: May 30th 2025 | Updated: June 5th 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across BordersPublished: April 18th 2025 | Updated: April 21st 2025
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
5
